

Poster 48

## Enantioseparation of 3-chloromethcathinone by liquid chromatography at the milligram scale

Ivan Langa<sup>1,2,3,4,\*</sup>, Cláudia Ribeiro<sup>1,2</sup>, Virgínia Gonçalves<sup>1,2,3</sup>, Diana Dias-da-Silva<sup>1,4,5,6,7</sup>, Sara Cravo<sup>8,9</sup> and Maria Tiritan<sup>1,2,8,9</sup>

<sup>1</sup> Associate Laboratory i4HB – Institute for Health and Bioeconomy, University Institute of Health Sciences – CESPU, 4585-116 Gandra, Portugal.

<sup>2</sup> UCIBIO – Applied Molecular Biosciences Unit, Translational Toxicology Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), 4585-116 Gandra, Portugal.

<sup>3</sup> UNIPRO – Oral Pathology and Rehabilitation Research Unit, University Institute of Health Sciences (IUCS-CESPU), 4585-116 Gandra, Portugal.

<sup>4</sup> UCIBIO – Applied Molecular Biosciences Unit, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.

<sup>5</sup> Associate Laboratory i4HB – Institute for Health and Bioeconomy, University of Porto, 4050-313 Porto, Portugal.

<sup>6</sup> REQUIMTE/LAQV, ESS, Polytechnic of Porto, Rua Dr. António Bernardino de Almeida, 400 4200-072, Porto, Portugal.

<sup>7</sup> UCIBIO – Applied Molecular Biosciences Unit, Forensics and Biomedical Sciences Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), 4585-116 Gandra, Portugal.

<sup>8</sup> Interdisciplinary Centre of Marine and Environmental Research (CIIMAR/CIMAR), University of Porto, Terminal de Cruzeiros do Porto de Leixões, 4450-208 Matosinhos, Portugal.

<sup>9</sup> Laboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.

\* Correspondence: a23700@alunos.cespu.pt

### Abstract

**Background:** The most prominent synthetic cathinone (SCAT) is 3-chloromethcathinone (3-CMC), accounting for 34% and 63.41% of the total seized new psychoactive substances (NPS) in Europe in 2021 and 2022, respectively [1, 2]. Over the latest years, since the first identification on the European drug market in September 2014 in Sweden, 3-CMC has gained significant popularity among the younger drug users [3]. Moreover, 3-CMC is chiral and its enantiomers can show different biological activity, highlighting the importance of the enantioselectivity studies in clinical, forensic and ecotoxicological context. **Objective:** The aim of this study was to optimize a chromatographic method for the enantiomeric separation of 3-CMC at the milligram scale for further use in *in vitro* and ecotoxicity assessments. **Methods:** The enantioseparation as well as the enantiomeric purity evaluation of the 3-CMC were performed by liquid chromatography coupled to the ultraviolet-visible detector (UV/Vis), using a CHIRALPAK<sup>®</sup> AD-H 10 x 250 mm, 5 µm, a semi-preparative column. A Dionex Ultimate 3000 automated fraction collector was used for fractions collection. Data was analyzed by Chromeleon 7.0 software. For method conditions optimization, a solution at 100 µg mL<sup>-1</sup> of 3-CMC in ethanol with diethylamine was used. **Results:** The optimized method allowed the separation of the enantiomers of 3-CMC at final concentration of 3.7 mg mL<sup>-1</sup>, with an enantiomeric purity of 98 % and 95 % for the first and second eluted enantiomer, respectively. The determination of the absolute configuration of the enantiomers is ongoing by electronic circular dichroism. **Conclusions:** The isolated enantiomers will be used for the enantioselective evaluation of the 3-CMC ecotoxicity. The determination of the absolute configuration of the enantiomers will enable correlating the ecotoxicity of each enantiomer.

**Keywords:** 3-chloromethcathinone; enantioseparation; synthetic cathinones

### Acknowledgments/Funding

This project was financed by FCT–Portuguese Foundation for Science and Technology, through the FCT/MCTES (PIDDAC), under the project PTDC/CTA-AMB/6686/2020 (ENANTIOTOX) and 2022.02842.PTDC – STAR - STereoselective environmental processes in Antibiotics: role for Resistance, with DOI 10.54499/2022.02842.PTDC (<https://doi.org/10.54499/2022.02842.PTDC>). Partially supported by national funds by FCT within the scope of Base Funding UIDB/04423/2020 and UIDP/04423/2020, UIDP/04423/2020 (Group of Marine Natural Products and Medicinal Chemistry-CIIMAR). Ivan Langa acknowledges a Ph.D. research grant provided by FCT 2022.12874.BD. This work was also partially supported by FCT/MCTES (PIDDAC) via institutional funding to the associate laboratory UCIBIO (DOI: 10.54499/LA/P/0140/2020) - Associate Laboratory i4HB and through the annual funding of 1H-TOXRUN of the University

Institute of Health Sciences (IUCS-CESPU). This work received support from the PT national funds (FCT/MECI, Fundação para a Ciência e Tecnologia and Ministério da Educação, Ciência e Inovação) through the project UID/50006 -Laboratório Associado para a Química Verde - Tecnologias e Processos Limpos.

## References

1. EMCDDA, European Drug Report 2023: *Trends and Developments*, **2023**.
2. EMCDDA, New psychoactive substances – The current situation in Europe (*European Drug Report 2024*, **2024**).
3. EMCDDA, Report on the risk assessment of 1-(3-chlorophenyl)-2-(methylamino)propan-1-one (3-chloromethcathinone, 3-CMC). **2022**, doi: 10.2810/671114.



In *Scientific Letters*, works are published under a CC-BY license (Creative Commons Attribution 4.0 International License at <https://creativecommons.org/licenses/by/4.0/>), the most open license available. The users can share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material for any purpose, even commercially), as long as they give appropriate credit, provide a link to the license, and indicate if changes were made (read the full text of the license terms and conditions of use at <https://creativecommons.org/licenses/by/4.0/legalcode>).